Skip Navigation

Cardiovascular Research 2001 50(1):85-96; doi:10.1016/S0008-6363(01)00201-2
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bénardeau, A.
Right arrow Articles by Nattel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bénardeau, A.
Right arrow Articles by Nattel, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs

Agnès Bénardeaua,c, Samir Fareha and Stanley Nattela,b,*

aDepartment of Medicine and Research Center, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada
bDepartment of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
cHoffman-La Roche Pharmaceuticals, Basel, Switzerland

* Corresponding author. Tel.: +1-514-376-3330, ext. 3990; fax: +1-514-376-1355 nattel{at}icm.umontreal.ca

Background: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca2+ current. There is also a clinical suggestion that acute L-type Ca2 channel blockade can promote AF, consistent with an AF promoting effect of Ca2+ channel inhibition. Methods: To evaluate the potential mechanisms of AF promotion by Ca2+ channel blockers, we administered verapamil to morphine–chloralose anesthetized dogs. Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments. Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF. Results: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8±4 s (mean±S.E.) to 95±39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228±101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg. Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil. In these experiments, verapamil shortened mean effective refractory period (ERP) from 122±5 to 114±4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15±1 to 10±1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94±4 to 84±3 ms, P<0.005). Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n = 5). In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness. Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade. Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle. Conclusions: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.

KEYWORDS Arrhythmia (mechanisms); Ion channels; Mapping; Remodeling


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel
The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy
Cardiovasc Res, April 1, 2007; 74(1): 104 - 113.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Caballero, R. Gomez, L. Nunez, I. Moreno, J. Tamargo, and E. Delpon
Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations
Cardiovasc Res, December 1, 2004; 64(3): 457 - 466.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Goette, U. Lendeckel, and H. U Klein
Signal transduction systems and atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 247 - 258.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Kurita, H. Mitamura, A. Shiroshita-Takeshita, A. Yamane, M. Ieda, O. Kinebuchi, T. Sato, S. Miyoshi, M. Hara, S. Takatsuki, et al.
Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling
Cardiovasc Res, May 1, 2002; 54(2): 447 - 455.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.